Lexicon Pharmaceuticals (LXRX) Other Non Operating Income (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has reported Other Non Operating Income for 17 consecutive years, with $1.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Non Operating Income fell 30.46% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $6.2 million (down 50.66% YoY), while the FY2025 annual figure was $6.9 million, down 43.8% from the prior year.
• Other Non Operating Income improved to $1.5 million in Q1 2026 per LXRX's latest filing, from $1.3 million in the prior quarter.
• Across five years, Other Non Operating Income topped out at $4.1 million in Q2 2024 and bottomed at $14000.0 in Q1 2022.
• Historically, Other Non Operating Income has averaged $1.8 million across 5 years, with a median of $1.6 million in 2025.
• Annual changes were most pronounced in 2022 — Other Non Operating Income sank 70.83% — and 2023, when it jumped 7250.0%.
• Lexicon Pharmaceuticals' Other Non Operating Income stood at $887000.0 in 2022, then soared by 170.8% to $2.4 million in 2023, then grew by 17.78% to $2.8 million in 2024, then slumped by 54.72% to $1.3 million in 2025, then climbed by 20.45% to $1.5 million in 2026.
• Business Quant data shows LXRX's Other Non Operating Income at $1.5 million in Q1 2026, $1.3 million in Q4 2025, and $1.6 million in Q3 2025.